Moleculin Biotech develops drug candidates for hard to treat cancers and viruses, led by Annamycin. It last closed at $6.83 on Nov 17, down 4.34% on the day.
Only 1 firm rated MBRX in the past 90 days, not enough for a consensus
Average 12-month target
$3.00
▼ 56.1% downside
Based on 1 analyst who set a price target on MBRX in the past 90 days. The average target is $3.00, with a high of $3.00 and a low of $3.00, compared with the last close of $6.83.
Low $3.00Avg $3.00High $3.00
Blue marker: last close $6.83
Highest target$3.00
Average target$3.00
Lowest target$3.00
Latest rating changes
HC Wainwright & Co.Maintained
Aug 28Buy$3
Date
Firm
Action
Rating
Price target
Aug 28
HC Wainwright & Co.
Maintained
Buy
$3
Loading…
Technical Analysis
MBRX · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold
The stock is 15% below its 20 day and 41% below its 50 day average. It is 420% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 37), near oversold. The nearest support is the Pivot S1 at $6.59, and the nearest resistance the Pivot at $7.05.
Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityNormal, 13.2%/day
Key levels
$229.4052 week high+3258.7%
$35.55200 day average+420.5%
$18.25100 day average+167.2%
$9.6350 day average+41.0%
$8.95Swing high (Nov 5)+31.0%
$7.8720 day average+15.2%
$7.28Pivot R1+6.6%
$7.05Pivot+3.2%
$6.83Last close
$6.59Pivot S1−3.5%
$4.42Swing low (Oct 19)−35.3%
$3.2352 week low−52.7%
Indicators
RSI (14)
36.74
Weak, oversold below 30
Neutral
MACD
-0.49
Above its signal line
Bullish
Stochastic
8.5
Near the bottom of its range
Oversold
ADX (14)
14.3
No clear trend
Williams %R
-99.1
Oversold below −80, overbought above −20
Oversold
CCI (20)
-73.0
Oversold below −100, overbought above 100
Neutral
Rate of change
−17.7%
Change over 10 sessions
Bearish
ATR (14)
$0.90
Typical daily range, 13.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 111.8%/day
Key levels
$229.4052 week high+3258.7%
$35.55200 day average+420.5%
$18.25100 day average+167.2%
$9.6350 day average+41.0%
$8.95Swing high (Nov 5)+31.0%
$7.8720 day average+15.2%
$7.28Pivot R1+6.6%
$7.05Pivot+3.2%
$6.83Last close
$6.59Pivot S1−3.5%
$4.42Swing low (Oct 19)−35.3%
$3.2352 week low−52.7%
Indicators
RSI (14)
31.08
Weak, oversold below 30
Neutral
MACD
-14.97
Above its signal line
Bullish
Stochastic
26.6
Middle of its range
Neutral
ADX (14)
25.3
Trending down
Williams %R
-82.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-64.7
Oversold below −100, overbought above 100
Neutral
Rate of change
−52.2%
Change over 10 sessions
Bearish
ATR (14)
$7.63
Typical daily range, 111.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for MBRX
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how MBRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow MBRX usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How MBRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MBRX is in one of them and how their past MBRX trades turned out.
Moleculin Biotech is a pharmaceutical development company based in Houston, Texas, that develops drug candidates for cancer and certain viruses. Its lead candidate, Annamycin, is an anthracycline chemotherapy agent being studied for relapsed or refractory acute myeloid leukemia and for soft tissue sarcoma that has spread to the lungs. Much of its research is carried out with academic investigators, including at MD Anderson Cancer Center in Houston.